Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Heinicke T, et al. Among authors: schulze a. Ann Hematol. 2021 Nov;100(11):2877-2878. doi: 10.1007/s00277-021-04638-1. Ann Hematol. 2021. PMID: 34529106 Free PMC article. No abstract available.
Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D; East German Study Group Hematology and Oncology (OSHO). Basara N, et al. Among authors: schulze a. Leukemia. 2009 Apr;23(4):635-40. doi: 10.1038/leu.2008.352. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151786 Clinical Trial.
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M; East German Study Group Hematology/Oncology (OSHO); Study Alliance Leukemia (SAL). Thiel A, et al. Among authors: schulze a. Ann Oncol. 2015 Jul;26(7):1434-40. doi: 10.1093/annonc/mdv205. Epub 2015 Apr 28. Ann Oncol. 2015. PMID: 25922062 Free article. Clinical Trial.
Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D. Kahl C, et al. Among authors: schulze a. J Cancer Res Clin Oncol. 2016 Jan;142(1):305-15. doi: 10.1007/s00432-015-2045-8. Epub 2015 Sep 25. J Cancer Res Clin Oncol. 2016. PMID: 26407768
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Heinicke T, et al. Among authors: schulze a. Ann Hematol. 2021 Sep;100(9):2387-2398. doi: 10.1007/s00277-021-04565-1. Epub 2021 Jul 7. Ann Hematol. 2021. PMID: 34232360 Free PMC article. Clinical Trial.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS. Niederwieser D, et al. Among authors: schulze a. Ann Hematol. 2023 Mar;102(3):547-561. doi: 10.1007/s00277-023-05087-8. Epub 2023 Jan 25. Ann Hematol. 2023. PMID: 36695874 Free PMC article.
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). Pönisch W, et al. Among authors: schulze a, schulze m. J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12. doi: 10.1007/s00432-005-0074-4. Epub 2006 Jan 10. J Cancer Res Clin Oncol. 2006. PMID: 16402269 Clinical Trial.
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C; East German Study Group Hematology and Oncology (OSHO). Herold M, et al. Among authors: schulze a, schulze m. J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12. doi: 10.1007/s00432-005-0023-2. Epub 2005 Aug 9. J Cancer Res Clin Oncol. 2006. PMID: 16088404 Clinical Trial.
930 results